Request Trial
11 September 2026NewsRegulation & IndustryMarisa Woutersen

Built to be bought? What makes companies acquisition-ready

For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
5 November 2026   Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.
Regulation & Industry
EPO starts using AI for minutes but no access to transcripts for parties
5 November 2026   From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available
Regulation & Industry
UK unveils £1bn sector investment push after recent setbacks
30 October 2026   With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
Irish law firms announce merger
How in-house teams can get more value from external counsel
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
In-house counsel rethink patent filing strategies as costs mount